These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies. Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035 [TBL] [Abstract][Full Text] [Related]
9. In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3β. Mishra P; Kesar S; Paliwal SK; Chauhan M; Madan K Cent Nerv Syst Agents Med Chem; 2018; 18(2):150-158. PubMed ID: 29848281 [TBL] [Abstract][Full Text] [Related]
10. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β. Kumar A; Srivastava G; Negi AS; Sharma A J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523 [TBL] [Abstract][Full Text] [Related]
11. Rational Design of Dual Inhibitors for Alzheimer's Disease: Insights from Computational Screening of BACE1 and GSK-3β. Sai Varshini M; Reddy RA; Krishnamurthy PT; Selvaraj D Curr Comput Aided Drug Des; 2024; 20(6):998-1012. PubMed ID: 37921183 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis. Benghanem S; Mesli F; Fatima Zohra HA; Nacereddine C; Hadjer C; Abdellatif M J Biomol Struct Dyn; 2024 Sep; 42(14):7091-7106. PubMed ID: 37498130 [TBL] [Abstract][Full Text] [Related]
13. Exploring Structural and Physicochemical Profiles of Potential GSK-3β Inhibitors Using Structure- and Ligand-Based Modeling Studies. Hossain T; Saha A; Mukherjee A Comb Chem High Throughput Screen; 2016; 19(4):298-306. PubMed ID: 27064095 [TBL] [Abstract][Full Text] [Related]
14. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK-3β inhibitors. Liu X; Yu J; Luo Y; Dong H Chem Biol Drug Des; 2023 Feb; 101(2):326-339. PubMed ID: 35762873 [TBL] [Abstract][Full Text] [Related]
15. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design. Darshit BS; Balaji B; Rani P; Ramanathan M J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440 [TBL] [Abstract][Full Text] [Related]
16. Biological evaluation and energetic analyses of novel GSK-3β inhibitors. Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel brain penetrant GSK-3β inhibitors toward Alzheimer's disease therapy by virtual screening, molecular docking, dynamic simulation, and MMPBSA analysis. Dasgupta A; Kalidass K; Farisha S; Saha R; Ghosh S; Ampasala DR J Biomol Struct Dyn; 2024 Oct; ():1-27. PubMed ID: 39427335 [TBL] [Abstract][Full Text] [Related]
18. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease. Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112 [TBL] [Abstract][Full Text] [Related]
19. Novel GSK-3beta inhibitors from sequential virtual screening. Kim HJ; Choo H; Cho YS; No KT; Pae AN Bioorg Med Chem; 2008 Jan; 16(2):636-43. PubMed ID: 18006321 [TBL] [Abstract][Full Text] [Related]